The current team is built with the specific idea of driving the Company through the first two Stages of development. Leadership and expertise are tailored to fulfill the needs of 1) managing product development from non-clinical toxicity stage through the end of Phase II trials and 2) Raising up to US$30MM to fund the development. After successful completion of Phase I clinical trials and interim reports on the Phase II trials the current management will be replaced with the team experienced with IPO and/or pharma acquisitions, and company will begin restructuring to be ready for large scale clinical development and marketing authorizations.

The bios of BT management are listed below: 

Dmitry Kravtsov, M.D.

Dmitry Kravtsov, M.D. is a biomedical scientist with over 15 years of experience in rare diseases. He received his doctorate degree in 2000 from Kuban State Medical University in Russia. After completion of his PGY1 in internal medicine, he joined Vanderbilt University as a post-doctoral researcher in 2001. 

During his time at Vanderbilt University, he studied the genetics of rare diseases focusing on the rare form of hemophilia, Factor XI deficiency. His work culminated with a novel classification of FXI deficiencies explaining co-existence of both autosomal dominant and recessive forms of the disease.

In 2009, Dr. Kravtsov joined Yale University School of Medicine as an Associate Research Scientist focusing on development of tissue-specific models of gastrointestinal disorders. While at Yale, he created unique models of Microvillus Inclusion Disease (MVID) and discovered novel concepts that changed the understanding of the pathogenesis of the disease.

He joined Vanessa Biotech in 2015 as Vice President of Research and Development. Dr. Kravtsov is leading the team of professionals that designs and tests novel antisecretory antidiarrheal drugs. He is an inventor with three patents on the pharmaceuticals.Dmitry Kravtsov, M.D.

Adrian Subia

Adrian Subia graduated from the University of Logroño in 1997 with a B.S. in chemistry and later a M. S. in Food Industry Engineering. All his career has been related to spirits development, production and quality assurance. For the past 20 years he has managed the business of the production facility for Spain’s number one indigenous liquor, called Pacharan. 

Mr. Subia’s expertise in producing a wide variety of liqueurs and gin allowed him to make a significant contribution to the development of the active ingredient in VB’s anti-diarrheal drugs.  He is named as a co-inventor on the Company’s patent application for the drug. 

In 2010, he was elected president of the Regulatory Council of the Geographical Indication Pacharan Navarro, a position he holds to date.Adel Egri

Rajeev Verma, Ph.D.

Rajeev is a broadly trained scientist providing molecular and cell biology expertise to the team at Vanessa Biotech. Rajeev started on the science career path in West Africa, where he trained as a microbiologist, obtaining an M.Sc. in medical microbiology from the University of Lagos. He moved to the United States to pursue further graduate training in the fields of Biotechnology and Cell biology, receiving the M.S. and Ph.D. degrees from the University of Connecticut. He spent his initial years as a research associate at UCONN, proving vital to the cloning and biochemical characterization of enzymes involved in the plant cell wall biosynthesis; functional expression of catalytic domains of receptor proteins involved in plant innate immune response pathways. He diversified his skills through a foray into the field of colon cancer research to elucidate the roles of an investigational pharmaceutical compound in DNA damage response pathways and the prevention of colon cancer. He was also a key research contributor in investigating the role of Hyperbaric Oxygen therapy in ameliorating diabetic kidney disease and the identification of potential early biomarkers of kidney disease.

Dr. Verma joined VB in 2019 and is currently leading the Cell Biology and Biochemistry Department, focusing on experimental research in the area of in-vitro cellular multi-dimensional systems, including organoid and stem cell research. 

Ildiko Ziegler

Adrian Subia Sainz

Rajeev Verma

Emilio Restoy Cabrera

ADVISORY BOARD

Emilio Restoy Cabrera

Mr. Restoy is the former CEO of a Spanish value-oriented wine and spirits’ conglomerate: Zamora Company. He graduated with a B.Sc. in Chemical Engineering from Madrid Complutense University. He later earned his MBA from the prestigious IESE and LA Anderson Business Schools. He climbed the corporate ladder to become the third generation CEO of the family business. Under his guidance and direction for 11 years Zamora grew to become a dominant player in the market segment and expanded the business beyond Spain into 70 countries.  In 2017, with the acquisition of a US based distiller, he opened the North American market. Mr. Restoy management skills include operations of global turnover of $200 million He is currently the President of the Spanish Wine Association. He is a co-founder and board member  of several startups in the food technology and healthcare industry.  He has relevant experience in the Start Up and Venture Capital space with P&L experience up to US$250 million.

Prof. Henry J. Binder, Emeritus

Prof. Binder FW ’65 is professor emeritus of medicine and of cellular and molecular physiology at the Yale University School of Medicine. He is senior research scientist who received the Solomon A. Berson Medical Alumni Achievement Award in Clinical Science from the NYU School of Medicine in May 2012.

He is also a world expert Gastroenterology specialist based in New Haven, Connecticut. He attended and graduated from New York University School of Medicine in 1961, and has over 60 years of diverse experience, especially in Gastroenterology.As a Wellcome Trust and Burroughs Wellcome Fund awardee he studied diarrheal diseases in developing countries. Prof. Binder, who is also director of the General Clinical Research Center at Yale, collaborated with colleagues in India and Scotland to develop an improved oral rehydration solution for diarrheal diseases, one of the most common causes of death among the world’s children. He also collaborated to develop a starch that improves the effectiveness of rehydration solutions by improving fluid absorption.Henry Binder